Rosetta Genomics (ROSG) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
Rosetta Genomics Reports 2016 First Quarter Financial Results
May 19, 2016 8:01 AM EDTRecord Quarterly Clinical Testing Revenues of $2.6 million
Conference call begins today at 10:00 a.m. Eastern time
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.
Recent developments include:
Expanded molecular diagnostics test menu with the launch of three new product offerings in common hematologic cancers and solid tumors; Received conditional approval status from... More